Real-world evidence (RWE) is a dynamic resource in establishing your medicine’s significance. It helps you comprehend the usefulness, safety, and cost of existing, and potential new remedy choices. Since requirements can range from operating areas, you need keys that are customized for you. The healthcare environment today is more technological, more competitive, and cost sensitive. Teams across the lifecycle need the right evidence to establish the significance of outgrowths and report difficult healthcare conclusions. There is increasing endorsement of RWE use from regulators, payers, prescribers, and patients - sparkling a new way of opportunities.
MarketsandMarkets helps you generate the right RWE to meet stakeholder needs with confidence and get real results just by attending our top-notch 5th Annual Real-World Evidence and Life Sciences Analytics Conference, in Boston, USA. With 4 successful events in RWE events that took place in the USA, here we are to announce the 5th Annual Real-World Evidence and Life Sciences Analytics Congress to be held on 20th – 21st October 2022.
Changes in healthcare analysis, treatments and planning during the pandemic have changed the innovation and reporting of some outcomes in data and the treated population. This means that disease trends may lead to incorrect interpretations when RWD and RWE are not framed in the context of the pandemic and long-term COVID-19 disease, therapy, and lifestyle changes. Telemedicine and virtual care may also provoke a greater adoption of technologies such as wearables and digital therapeutics, thus accelerating digitalization in the healthcare space and boosting the importance of RWE and AI.
Enquiry More About Conference @ https://events.marketsandmarkets.com/5th-annual-marketsandmarkets-real-world-evidence-and-life-science-analytics-conference/enquiry
This 5th Annual MarketsandMarkets Real-World Evidence and Life Science Analytics Congress will emphasis on above said major points and hold conversations on the best ways embraced by several stakeholders with a key takeaway being better decision-making.
Key Highlights
- The regulatory view around data quality data standards.
- Leveraging RWE for improving market access.
- The adoption role of AI ML in clinical trials.
- Real-world evidence Digital Health - The expanded role of RWE for digital health.
- Panel Discussion on lessons learned from the recent results of the FDA’s pilot program RCT DUPLICATE.
- Real-World Data Advanced Analytics.
- RWE to inform the decision-making process in rare diseases where there is a lack of evidence.
Do not miss this excellent opportunity, where you can witness the participation of some best Experts and get a chance to interact, have one-to-one meetings with one of your top prospects and get a chance to have a dedicated networking time with them.
You can also avail for customize sponsorship package the way you want.
Book your slot now by registering online or writing to us at [email protected] for more details.
